Radiodermatitis Market Outlook 2031:
The global radiodermatitis market size was valued at USD 412.60 Million in 2022 and is projected to reach USD 582.20 Million by 2031, expanding at a CAGR of 3.9% during the forecast period 2023 - 2031. The growth of the market is attributed to the growing number of patients suffering from skin cancer and rising demand for the cancer treatment.
Radiodermatitis, also known as radiation-induced skin reactions, is a type of skin cancer that has occurred as a side effect of ionizing radiation to the skin due to exposing to radiation. This is mainly caused due to some disasters such as nuclear radiation.
The market is significantly boosted due to the rising number of cancer patients who are experiencing a cutaneous reaction as a result of radiation therapy or radiotherapy during cancer treatment. This led to rising need for clinical emergency to cure this side effect, driving demand for urgent requirement for the effective treatment products and methods.
A significant acceptance of radiodermatitis products to improve quality of life presents a key insight of the market. This is expected to result in positive influence on the market.
The growing number of healthcare initiatives from both private & public authorities is continuously striving to foster awareness on the cancer treatment. Additionally, these organizations circulate guidelines and recommendations to treat the condition efficiently.
For instance, Provincial Health Services Authority circulated guidelines on radiodermatitis symptom management and information consisting of the disorder risk elements. This is projected to promote awareness with respect to treatment procedures and general skincare suggestions.
Radiodermatitis Market Trends, Drivers, Restraints, and Opportunities
- Wide number of patients suffering from radiodermatitis and skin cancer is expected to accelerate the market growth.
- Rapid adoption of radiotherapy for the cancer treatment is expected to drive the market growth at a rapid pace in the coming years.
- Rising government participation and introduction of public healthcare policies to spread awareness of several types of cancer are key drivers of the market.
- Expansion of clinical studies and wide research activities for improving the development of radiodermatitis treatment methods are expected to present several significant growth opportunities of the market.
- Availability of a wide range of innovative cancer treatment products to meet the needs for different requirements of patients are expected to boost the future growth of the market.
- High cost of radiotherapy and issues concerning the lack of prolonged improvement of cancer patients are key challenges that can hamper the market growth.
Scope of Radiodermatitis Market Report
The report on the global radiodermatitis market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Radiodermatitis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Years
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Topical [Antibiotics, Hydrophilic Creams, Corticosteroids, and Others], Oral, and Dressings [No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressings, Hydrogel & Hydrocolloid Dressings, and Others]), and Distribution Channels (Retail Pharmacy, Hospital Pharmacy, and Online)
|
|
Regional Scopes
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
ICON Plc.; Charles River Laboratory; ICON Plc.; Taconic Biosciences; Covance; EVOTEC SE; Eurofins Scientific; The Jackson Laboratory; MI Bioresearch, Inc.; Living Tumor Laboratory; Wuxi AppTec Champion Oncology, Inc.; XenTech; and Crown Bioscience International
|
Radiodermatitis Market Segment Insights
Dressings segment is expected to grow at a rapid pace
Based on products, the global radiodermatitis market is divided into topical, oral, and dressings. The topical segment is further segmented into antibiotics, hydrophilic creams, corticosteroids, and others. The dressings segment is sub-divided into no sting barrier film, honey impregnated gauze, silicone coated dressings, hydrogel & hydrocolloid dressings, and others.
The dressings segment is anticipated to expand at a rapid pace during the projected period owing to wide range of products in the market. However, the topical segment is expected to account for a key share of the market during the forecast period due to gold standard in the treatment of inflammatory skin conditions.
Retail pharmacy segment is projected to expand at a considerable CAGR
On the basis of distribution channels, the market is segregated into retail pharmacy, hospital pharmacy, and online. The retail pharmacy segment is projected to expand at a considerable CAGR during the forecast period owing to high accessibility and affordability linked with retail stores.
Meanwhile, the online segment is anticipated to hold a large market share during the forecast period due to various advantages such as increased convenience for patients.
Asia Pacific is anticipated to constitute a major market share
In terms of regions, the global radiodermatitis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific accounted for a key share of the market in 2019 and is anticipated to constitute a major market share in the coming years owing to expanding cancer patient base present in the region.
The market of North America, however, is expected to exhibit a high growth rate during the targeted period due to high investment on research and development activities in the region.
Segments
The global radiodermatitis market has been segmented on the basis of
Products
- Topical
- Antibiotics
- Hydrophilic Creams
- Corticosteroids
- Others
- Oral
- Dressings
- No Sting Barrier Film
- Honey Impregnated Gauze
- Silicone Coated Dressings
- Hydrogel & Hydrocolloid Dressings
- Others
Distribution Channels
- Retail Pharmacy
- Hospital Pharmacy
- Online
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- ICON Plc.
- Charles River Laboratory
- Taconic Biosciences
- Covance
- EVOTEC SE
- Eurofins Scientific
- The Jackson Laboratory
- MI Bioresearch, Inc.
- Living Tumor Laboratory
- Wuxi AppTec Champion Oncology, Inc.
- XenTech
- Crown Bioscience International.
Competitive Landscape
Key players competing in the global radiodermatitis market are ICON Plc.; Charles River Laboratory; Taconic Biosciences; Covance; EVOTEC SE; Eurofins Scientific; The Jackson Laboratory; MI Bioresearch, Inc.; Living Tumor Laboratory; Wuxi AppTec Champion Oncology, Inc.; XenTech; and Crown Bioscience International.
These main market players are continuously engaged in wide range of business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market positions. For instance, ConvaTec introduced new sizes for its product, AQUACEL Foam dressings in May 2016.
Request For Customization
Enquiry Before Buying
Speak With Analyst
